Based upon the titration of myeloid cells: T-cells in culture, CD11b+GR-1+ IMCs from non-tumor-bearing mice and CD11b+GR-1+ MDSCs from tumor-bearing mice had nearly equivalent potency as assessed by the myeloid: T-cell ratio sufficient to achieve half-maximal suppression of T-cell proliferation (Fig. 3B). This evidence concerns the gene ITGAM and neoplasm.